About Us

Pipeline:

Commercial Opportunity:

Established KORSUVA™ IV Commercial Partnerships:

2021 Projected Milestones:

Dec 31st, 2020 Financial Information:

Stock Information:

CARA

ExchangeNASDAQ

Analyst Coverage:

Financial Guidance:

Board of Directors:

Management Team:

Corporate Events:

4/12/2021 Needham & Co. Annual Healthcare Conference

05/10/2021 Q1 Earnings Release Date

Contact Information:

investor@caratherapeutics.com

The FDA has conditionally accepted KORSUVA™ as the trade name for CR845 / difelikefalin for pruritic indications. CR845 / difelikefalin is an investigational drug product, and its safety and efficacy have not been fully evaluated by any regulatory authority.

^ Commercialization rights to CR845 in defined indications - Japan: Maruishi Pharma; South Korea: CKD Pharma.

  • Breakthrough Designation for IV CR845 for Pruritus CKD-HD; Q1 2021 NDA accepted with priority review. # VFMCRP and Cara have rights to promote in Fresenius Medical Care dialysis clinics in the US under a profit share agreement.
  • Vifor has commercial rights in Non-US Fresenius clinics under a profit-share arrangement. CKD-HD: Chronic Kidney Disease- Hemodialysis; PBC: Primary Biliary Cholangitis; NP: Notalgia Paresthetica

1Source: 1IQVIA Analysis, 2013.

© 2021 Cara Therapeutics, Inc. All Rights Reserved. April 2021

Attachments

  • Original document
  • Permalink

Disclaimer

CARA Therapeutics Inc. published this content on 05 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 April 2021 15:03:01 UTC.